Table 1.
Completed cardiovascular outcome trials for DPP4 inhibitors and GLP-1R agonist
| Study | Drug (Sponsor) | Phase | Study Design | Duration (weeks) | Intervention Arms Dosage (N)+ | Hazard Ratio, 95% CI, (p value) |
|---|---|---|---|---|---|---|
| DPP4 Inhibitors | ||||||
| SAVOR-TIMI 53 | Saxagliptin (AstraZeneca) | 4 | RCT/DB | 104 | Saxagliptin 5 mg or 2.5 mg (8280) | 1.00, 0.89-1.12, (0.99) |
| Placebo (8212) | ||||||
| EXAMINE | Alogliptin (Takeda) | 3 | RCT/DB | 160 | Alogliptin 25/12.5/6.25 mg (2701) | 0.96, 1.16*, (0.32) |
| Placebo (2679) | ||||||
| TECOS | Sitagliptin (Merck Sharp & Dohme Corp.) | 3 | RCT/DB | 156 | Sitagliptin 100 mg or 50 mg (7332) | 0.98, 0.88-1.09, (NS) |
| Placebo (7339) | ||||||
| GLP-1 Receptor Agonists | ||||||
| ELIXA | Lixisenatide (Sanofi) | 3 | RCT/DB | 108 | Lixisenatide 10-20 μg (3034) | 1.02, 0.89-1.17, (NS) |
| Placebo (3034) | ||||||
DB, double blind; NS, not significant; RCT, randomized control trial;
*
the upper boundary of the one-sided repeated confidence interval, at an alpha level of 0.01.